|
Dear Reader :
The year is drawing to a close but there’s still plenty of pharma action underway, including a flurry of deal-making.
This month’s newsletter, co-developed by the IPA and Citeline, captures the big splash M&A deals by AbbVie and also gives you a glimpse of what to expect in the high-stakes oral incretins space. Plus, we feature a piece on Novo Nordisk Foundation’s Mads Krogsgaard Thomsen, who supervised the development semaglutide.
Before we sign off for 2023, here’s wishing you a merry Christmas and plenty of holiday cheer ahead!
Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA
|
